FIELD: pharmacology.SUBSTANCE: group of inventions is described comprising an antibody or an antigen-binding fragment thereof that binds to PD-1； a humanized antibody or antigen-binding fragment thereof； a pharmaceutical composition for treatment of a disease associated with B7-H1 interaction with PD-1； a method for malignant tumour treatment in an individual, as well as a method for treatment of an infectious disease associated with the B7-H1 interaction with PD-1, wherein the above methods comprise administration of a pharmaceutical composition； application of the above antibody or antigen-binding fragment for preparation of a drug for malignant tumour treatment, as well as for preparation of a drug for treatment of an infectious disease associated with the B7-H1 interaction with PD-1； method for detection or diagnosis of a disease, disorder or infection associated with B7-H1 interaction with PD-1, method to monitor the disease, disorder or infection progression, method to monitor the response to disease, disorder or infection treatment, method for treatment of a disease associated with an increased PD-1 expression, method for treatment of diseases associated with an increased expression of B7-H1, where the methods include application of the aforementioned antibody or the antigen-binding fragment thereof.EFFECT: invention extends the arsenal of antibodies that bind to PD-1.37 cl, 20 dwg, 23 tbl, 7 exИзобретение относится к области биохимии. Описана группа изобретений, включающая антитело или его антигенсвязывающий фрагмент, которые связываются с PD-1； гуманизированное антитело или его антиген-связывающий фрагмент； фармацевтическая композиция для лечения заболевания, связанного со взаимодействием В7-Н1 с PD-1； способ лечения злокачественной опухоли у индивидуума, а также способ лечения инфекционного заболевания, связанного со взаимодействием В7-Н1 с PD-1, где вышеуказанные способы включают введение фармацевтической композиции； применение вышеуказанного антитела или
